Inclusion Criteria:

1. Diagnosis of adenocarcinoma of the prostate.

2. Male, age greater than or equal to 45 years.

3. Intact prostate of at least 30g, as estimated by physical estimation and/or
ultrasound.

4. ECOG (Eastern Cooperative Oncology Group) performance status of 0 or 1.

5. Patients must be planned to have external beam radiation as the definitive treatment
for their prostate cancer with treatment set-up verification according to a locally
fixed protocol.

6. Patients must have anatomy that will allow an adequate pelvic imaging by CBCT as well
as CT scanning.

7. Organ confined or locally advanced prostate cancer with clinical N category 0 or x, M
category 0 or x.

8. Ability to comply with study visit schedule.

9. Patient (or legal guardian) understands the study requirements and the
investigational procedure and provides written Informed Consent before any
study-specific tests or procedures are performed.

Exclusion Criteria:

1. Past history of abdominoperineal (A-P) resection.

2. Planned course of treatment using brachytherapy (permanent brachytherapy seeds or
high dose rate [HDR] brachytherapy).

3. Allergy to local anesthetics.

4. History of chronic prostatitis.

5. Patients with history of recent acute and/or chronic bleeding disorders.

6. Patients on therapeutic anti-coagulants or anti-platelet therapy, not including
aspirin or dipyridamole.

7. Patients for which the maximum body width or the maximum anterior-posterior depth in
the abdomino-pelvic region is greater than 40 cm. (Measurements will be made visually
with a ruler.)

8. Patients with a body habitus that the CT bore of the CT/LINAC treatment machine
cannot accommodate.

9. Patients with a prior history of pelvic or prostate radiotherapy.

10. Patients who have had prior prostate surgery other than a TUR.

11. Cognitively impaired patients who cannot give informed consent.

12. Patients with hip replacement by a metal prosthesis.

13. Patient has participated in, or is planned to participate in, any investigational
drug or device study within the past or next 2 months.

14. Patient who has more than 1μCi of any injected or implanted radioactive material
within his body.